Abstract
Iressa® (ZD1839) is a new anticancer agent, acting as a selective epidermal growth factor receptor tyrosine kinase inhibitor. Iressa® has been generally well-tolerated in cancer patients. Predominant adverse effects are an acne-like skin rash, diarrhea, nausea, vomiting, dry skin, and mild to moderate myelosuppression. The side effect of paronychia or alopecia is rare. We report a case of paronychia with granulation tissue induced by Iressa®. Our patient complained of an acneiform eruption on his face and xerosis on his left arm and both feet as well as paronychia of several finger and toe nails.
| Original language | English |
|---|---|
| Pages (from-to) | 665-668 |
| Number of pages | 4 |
| Journal | Korean Journal of Dermatology |
| Volume | 42 |
| Issue number | 5 |
| State | Published - May 2004 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Acneiform eruption
- Iressa® (ZD1839)
- Paronychia
- Xerosis
Fingerprint
Dive into the research topics of 'A case of paronychia, acneiform eruption and dry skin induced by iressa®'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver